Champions Oncology
CSBR
47 hedge funds and large institutions have $76.9M invested in Champions Oncology in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
17% more capital invested
Capital invested by funds: $65.5M → $76.9M (+$11.4M)
2% more funds holding
Funds holding: 46 → 47 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.32% less ownership
Funds ownership: 55.66% → 53.34% (-2.3%)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Roubaix Capital
Denver,
Colorado
|
+$2.13M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.03M |
| 3 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$642K |
| 4 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$413K |
| 5 |
State Street
Boston,
Massachusetts
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.21M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$556K |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
-$257K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$224K |
| 5 |
Renaissance Technologies
New York
|
-$189K |
CSBR Hedge Fund Activity: Q4 2020 in Review
47 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2020, worth a combined $76.9M — up 17% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CSBR positions and 3 closed out — a net gain of 3 holders — while 12 added to existing stakes and 19 trimmed.
The largest buyer was Roubaix Capital, opening a new position worth an estimated $2.13M. The largest seller was Vanguard Group, cutting an estimated $2.21M.
- 47 institutional investors held Champions Oncology (CSBR) as of Q4 2020, up from 46 in Q3 2020.
- Funds reported $76.9M of Champions Oncology stock for Q4 2020, up 17% quarter-over-quarter.
- 6 funds opened new Champions Oncology positions in Q4 2020 and 3 closed out, a net change of +3 holders.
- The largest Champions Oncology buyer in Q4 2020 was Roubaix Capital, an estimated $2.13M added.
- The largest Champions Oncology seller in Q4 2020 was Vanguard Group, an estimated $2.21M sold.
Based on aggregated 13F filings for Q4 2020.